{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:55:50Z","timestamp":1791255350111,"version":"4.1.0"},"reference-count":164,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002001","name":"Health and Social Care Delivery Research (HSDR) Programme","doi-asserted-by":"publisher","award":["15\/12\/22"],"award-info":[{"award-number":["15\/12\/22"]}],"id":[{"id":"10.13039\/501100002001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Soc Care Deliv Res"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Clinical guidelines commonly recommend preventative treatments for people above a risk threshold. Therefore, decision-makers must have faith in risk prediction tools and model-based cost-effectiveness analyses for people at different levels of risk. Two problems that arise are inadequate handling of competing risks of death and failing to account for direct treatment disutility (i.e. the hassle of taking treatments). We explored these issues using two case studies: primary prevention of cardiovascular disease using statins and osteoporotic fracture using bisphosphonates.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title>\n<jats:p>Externally validate three risk prediction tools [QRISK\u00ae3, QRISK\u00ae-Lifetime, QFracture-2012 (ClinRisk Ltd, Leeds, UK)]; derive and internally validate new risk prediction tools for cardiovascular disease [competing mortality risk model with Charlson Comorbidity Index (CRISK-CCI)] and fracture (CFracture), accounting for competing-cause death; quantify direct treatment disutility for statins and bisphosphonates; and examine the effect of competing risks and direct treatment disutility on the cost-effectiveness of preventative treatments.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Design, participants, main outcome measures, data sources<\/jats:title>\n<jats:p>Discrimination and calibration of risk prediction models (Clinical Practice Research Datalink participants: aged 25\u201384 years for cardiovascular disease and aged 30\u201399 years for fractures); direct treatment disutility was elicited in online stated-preference surveys (people with\/people without experience of statins\/bisphosphonates); costs and quality-adjusted life-years were determined from decision-analytic modelling (updated models used in National Institute for Health and Care Excellence decision-making).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Results<\/jats:title>\n<jats:p>CRISK-CCI has excellent discrimination, similar to that of QRISK3 (Harrell\u2019s <jats:italic>c<\/jats:italic> = 0.864 vs. 0.865, respectively, for women; and 0.819 vs. 0.834, respectively, for men). CRISK-CCI has systematically better calibration, although both models overpredict in high-risk subgroups. People recommended for treatment (10-year risk of \u2265\u200910%) are younger when using QRISK-Lifetime than when using QRISK3, and have fewer observed events in a 10-year follow-up (4.0% vs. 11.9%, respectively, for women; and 4.3% vs. 10.8%, respectively, for men). QFracture-2012 underpredicts fractures, owing to under-ascertainment of events in its derivation. However, there is major overprediction among people aged 85\u201399 years and\/or with multiple long-term conditions. CFracture is better calibrated, although it also overpredicts among older people. In a time trade-off exercise (<jats:italic>n<\/jats:italic> = 879), statins exhibited direct treatment disutility of 0.034; for bisphosphonates, it was greater, at 0.067. Inconvenience also influenced preferences in best\u2013worst scaling (<jats:italic>n<\/jats:italic> = 631). Updated cost-effectiveness analysis generates more quality-adjusted life-years among people with below-average cardiovascular risk and fewer among people with above-average risk. If people experience disutility when taking statins, the cardiovascular risk threshold at which benefits outweigh harms rises with age (\u2265\u20098% 10-year risk at 40 years of age; \u2265\u200938% 10-year risk at 80 years of age). Assuming that everyone experiences population-average direct treatment disutility with oral bisphosphonates, treatment is net harmful at all levels of risk.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Limitations<\/jats:title>\n<jats:p>Treating data as missing at random is a strong assumption in risk prediction model derivation. Disentangling the effect of statins from secular trends in cardiovascular disease in the previous two decades is challenging. Validating lifetime risk prediction is impossible without using very historical data. Respondents to our stated-preference survey may not be representative of the population. There is no consensus on which direct treatment disutilities should be used for cost-effectiveness analyses. Not all the inputs to the cost-effectiveness models could be updated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Conclusions<\/jats:title>\n<jats:p>Ignoring competing mortality in risk prediction overestimates the risk of cardiovascular events and fracture, especially among older people and those with multimorbidity. Adjustment for competing risk does not meaningfully alter cost-effectiveness of these preventative interventions, but direct treatment disutility is measurable and has the potential to alter the balance of benefits and harms. We argue that this is best addressed in individual-level shared decision-making.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-7\"><jats:title>Study registration<\/jats:title>\n<jats:p>This study is registered as PROSPERO CRD42021249959.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-8\"><jats:title>Funding<\/jats:title>\n<jats:p>This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: 15\/12\/22) and is published in full in <jats:italic>Health and Social Care Delivery Research<\/jats:italic>; Vol. 12, No. 4. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/kltr7714","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T10:55:54Z","timestamp":1709204154000},"page":"1-275","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-4880","authenticated-orcid":true,"given":"Bruce","family":"Guthrie","sequence":"first","affiliation":[{"name":"Advanced Care Research Centre, Centre for Population Health Sciences, Usher Institute, The University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9339-7374","authenticated-orcid":true,"given":"Gabriel","family":"Rogers","sequence":"additional","affiliation":[{"name":"Manchester Centre for Health Economics, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4621-8713","authenticated-orcid":true,"given":"Shona","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Population Health and Genomics Division, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-8069","authenticated-orcid":true,"given":"Daniel R","family":"Morales","sequence":"additional","affiliation":[{"name":"Population Health and Genomics Division, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-0610","authenticated-orcid":true,"given":"Peter","family":"Donnan","sequence":"additional","affiliation":[{"name":"Population Health and Genomics Division, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-4287","authenticated-orcid":true,"given":"Sarah","family":"Davis","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-495X","authenticated-orcid":true,"given":"Ji Hee","family":"Youn","sequence":"additional","affiliation":[{"name":"Open Health Group, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3475-800X","authenticated-orcid":true,"given":"Rob","family":"Hainsworth","sequence":"additional","affiliation":[{"name":"Manchester Centre for Health Economics, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-5107","authenticated-orcid":true,"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[{"name":"Manchester Centre for Health Economics, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-4350","authenticated-orcid":true,"given":"Katherine","family":"Payne","sequence":"additional","affiliation":[{"name":"Manchester Centre for Health Economics, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"key2024022916234200_ref1-bib1","doi-asserted-by":"crossref","first-page":"e6341","DOI":"10.1136\/bmj.e6341","article-title":"Adapting clinical guidelines to take account of multimorbidity","volume":"345","author":"Guthrie","year":"2012","journal-title":"BMJ"},{"key":"key2024022916234200_ref2-bib2","doi-asserted-by":"crossref","DOI":"10.3310\/hsdr05160","article-title":"Better guidelines for better care: accounting for multimorbidity in clinical guidelines structured examination of exemplar guidelines and health economic modelling","volume":"5","author":"Guthrie","year":"2017","journal-title":"Health Serv Deliv Res"},{"key":"key2024022916234200_ref3-bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13063-020-4139-0","article-title":"Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review","volume":"21","author":"He","year":"2020","journal-title":"Trials"},{"key":"key2024022916234200_ref4-bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"key2024022916234200_ref5-bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","article-title":"The rising tide of polypharmacy and drug\u2013drug interactions: population database analysis 1995\u20132010","volume":"13","author":"Guthrie","year":"2015","journal-title":"BMC Med"},{"key":"key2024022916234200_ref6-bib6","doi-asserted-by":"crossref","first-page":"h949","DOI":"10.1136\/bmj.h949","article-title":"Drug\u2013disease and drug\u2013drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines","volume":"350","author":"Dumbreck","year":"2015","journal-title":"BMJ"},{"key":"key2024022916234200_ref7-bib7","doi-asserted-by":"crossref","first-page":"b2803","DOI":"10.1136\/bmj.b2803","article-title":"We need minimally disruptive medicine","volume":"339","author":"May","year":"2009","journal-title":"BMJ"},{"key":"key2024022916234200_ref8-bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ageing\/afs100","article-title":"Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity","volume":"42","author":"Hughes","year":"2013","journal-title":"Age Ageing"},{"key":"key2024022916234200_ref9-bib9","volume-title":"A Systematic Review of the Applicability of Clinical Trial Evidence to Real-world Patients","author":"He","year":"2016"},{"key":"key2024022916234200_ref13-bib13","volume-title":"Surveillance Proposal Consultation Document: Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification NICE Guideline CG181\u20134-Year Surveillance Review","author":"National Institute for Health and Care Excellence"},{"key":"key2024022916234200_ref14-bib14","doi-asserted-by":"crossref","first-page":"b2584","DOI":"10.1136\/bmj.b2584","article-title":"An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study","volume":"339","author":"Collins","year":"2009","journal-title":"BMJ"},{"key":"key2024022916234200_ref15-bib15","doi-asserted-by":"crossref","first-page":"c2442","DOI":"10.1136\/bmj.c2442","article-title":"An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study","volume":"340","author":"Collins","year":"2010","journal-title":"BMJ"},{"key":"key2024022916234200_ref16-bib16","doi-asserted-by":"crossref","first-page":"e4181","DOI":"10.1136\/bmj.e4181","article-title":"Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2","volume":"344","author":"Collins","year":"2012","journal-title":"BMJ"},{"key":"key2024022916234200_ref17-bib17","doi-asserted-by":"crossref","first-page":"b4229","DOI":"10.1136\/bmj.b4229","article-title":"Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFracture scores","volume":"339","author":"Hippisley-Cox","year":"2009","journal-title":"BMJ"},{"key":"key2024022916234200_ref18-bib18","doi-asserted-by":"crossref","first-page":"d3651","DOI":"10.1136\/bmj.d3651","article-title":"Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFracture scores","volume":"342","author":"Collins","year":"2011","journal-title":"BMJ"},{"key":"key2024022916234200_ref19-bib19","doi-asserted-by":"crossref","first-page":"e005809","DOI":"10.1136\/bmjopen-2014-005809","article-title":"The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study","volume":"4","author":"Hippisley-Cox","year":"2014","journal-title":"BMJ Open"},{"key":"key2024022916234200_ref20-bib20","doi-asserted-by":"crossref","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"key2024022916234200_ref21-bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2288-14-40","article-title":"External validation of multivariable prediction models: a systematic review of methodological conduct and reporting","volume":"14","author":"Collins","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"key2024022916234200_ref22-bib22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref24-bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"New Engl J Med"},{"key":"key2024022916234200_ref25-bib25","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"key2024022916234200_ref26-bib26","doi-asserted-by":"crossref","first-page":"e3427","DOI":"10.1136\/bmj.e3427","article-title":"Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study","volume":"344","author":"Hippisley-Cox","year":"2012","journal-title":"BMJ"},{"key":"key2024022916234200_ref27-bib27","doi-asserted-by":"crossref","first-page":"c6624","DOI":"10.1136\/bmj.c6624","article-title":"Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database","volume":"341","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"key2024022916234200_ref28-bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX \u2122 and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref29-bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/sim.4384","article-title":"Competing risks and the clinical community: irrelevance or ignorance?","volume":"31","author":"Koller","year":"2012","journal-title":"Stat Med"},{"key":"key2024022916234200_ref30-bib30","doi-asserted-by":"crossref","first-page":"g5060","DOI":"10.1136\/bmj.g5060","article-title":"Interpreting and comparing risks in the presence of competing events","volume":"349","author":"Wolkewitz","year":"2014","journal-title":"BMJ"},{"key":"key2024022916234200_ref31-bib31","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1093\/eurheartj\/ehu131","article-title":"Competing risks analyses: objectives and approaches","volume":"35","author":"Wolbers","year":"2014","journal-title":"Eur Heart J"},{"key":"key2024022916234200_ref32-bib32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/sim.2655","article-title":"Analysing and interpreting competing risk data","volume":"26","author":"Pintilie","year":"2007","journal-title":"Stat Med"},{"key":"key2024022916234200_ref33-bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/pst.200","article-title":"Power and sample size considerations in clinical trials with competing risk endpoints","volume":"5","author":"Maki","year":"2006","journal-title":"Pharm Stat"},{"key":"key2024022916234200_ref34-bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/EDE.0b013e3181a39056","article-title":"Prognostic models with competing risks: methods and application to coronary risk prediction","volume":"20","author":"Wolbers","year":"2009","journal-title":"Epidemiology"},{"key":"key2024022916234200_ref35-bib35","doi-asserted-by":"crossref","first-page":"e106455","DOI":"10.1371\/journal.pone.0106455","article-title":"Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?","volume":"9","author":"van Staa","year":"2014","journal-title":"PLOS ONE"},{"key":"key2024022916234200_ref36-bib36","doi-asserted-by":"crossref","first-page":"e1001361","DOI":"10.1371\/journal.pmed.1001361","article-title":"Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study","volume":"9","author":"Ferket","year":"2012","journal-title":"PLOS Med"},{"key":"key2024022916234200_ref39-bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00019053-200826090-00009","article-title":"Subgroups and heterogeneity in cost-effectiveness analysis","volume":"26","author":"Sculpher","year":"2008","journal-title":"PharmacoEconomics"},{"key":"key2024022916234200_ref40-bib40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40273-015-0357-9","article-title":"Do pills have no ills? Capturing the impact of direct treatment disutility","volume":"34","author":"Thompson","year":"2016","journal-title":"PharmacoEconomics"},{"key":"key2024022916234200_ref41-bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0272989X17700846","article-title":"Using the payoff time in decision-analytic models: a case study for using statins in primary prevention","volume":"37","author":"Thompson","year":"2017","journal-title":"Med Decis Making"},{"key":"key2024022916234200_ref42-bib42","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0272989X14538705","article-title":"The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application","volume":"34","author":"Espinoza","year":"2014","journal-title":"Med Decis Making"},{"key":"key2024022916234200_ref43-bib43","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"key2024022916234200_ref44-bib44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","article-title":"Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era","volume":"124","author":"Lazar","year":"2011","journal-title":"Circulation"},{"key":"key2024022916234200_ref45-bib45","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/jamainternmed.2014.2894","article-title":"Effect of patients\u2019 risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus","volume":"174","author":"Vijan","year":"2014","journal-title":"JAMA Intern Med"},{"key":"key2024022916234200_ref46-bib46","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/archinternmed.2010.150","article-title":"Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus","volume":"170","author":"Timbie","year":"2010","journal-title":"Arch Intern Med"},{"key":"key2024022916234200_ref47-bib47","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1161\/CIRCULATIONAHA.113.007595","article-title":"Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility","volume":"129","author":"Fontana","year":"2014","journal-title":"Circulation"},{"key":"key2024022916234200_ref48-bib48","doi-asserted-by":"crossref","first-page":"e006505","DOI":"10.1136\/bmjopen-2014-006505","article-title":"Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey","volume":"5","author":"Hutchins","year":"2015","journal-title":"BMJ Open"},{"key":"key2024022916234200_ref49-bib49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12872-023-03209-8","article-title":"External validation of the QLifetime cardiovascular risk prediction tool: population cohort study","volume":"23","author":"Livingstone","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"key2024022916234200_ref50-bib50","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S2666-7568(22)00290-2","article-title":"Predictive performance of a competing risk fracture prediction tool CFracture compared to QFracture in older people and those with comorbidity: population cohort study","volume":"4","author":"Livingstone","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"key2024022916234200_ref51-bib51","doi-asserted-by":"crossref","first-page":"e000316","DOI":"10.1136\/bmjmed-2022-000316","article-title":"Impact of competing mortality risks on predictive performance of the QFracture risk prediction tool for major osteoporotic fracture and hip fracture: external validation cohort study in a UK primary care population","volume":"1","author":"Livingstone","year":"2022","journal-title":"BMJ Med"},{"key":"key2024022916234200_ref52-bib52","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1056\/NEJMsa1508955","article-title":"Safer P prescribing \u2013 a trial of education, informatics, and financial incentives","volume":"374","author":"Dreischulte","year":"2016","journal-title":"N Engl J Med"},{"key":"key2024022916234200_ref53-bib53","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"key2024022916234200_ref54-bib54","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2009"},{"key":"key2024022916234200_ref55-bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"key2024022916234200_ref56-bib56","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.diabet.2013.07.002","article-title":"Comparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus","volume":"39","author":"Echouffo-Tcheugui","year":"2013","journal-title":"Diabetes Metab"},{"key":"key2024022916234200_ref57-bib57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdiacomp.2018.10.010","article-title":"Prognostic tools for cardiovascular disease in patients with type 2 diabetes: a systematic review and meta-analysis of C-statistics","volume":"33","author":"Chowdhury","year":"2019","journal-title":"J Diabetes Complications"},{"key":"key2024022916234200_ref58-bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00125-012-2772-1","article-title":"Prediction and classification of cardiovascular disease risk in older adults with diabetes","volume":"56","author":"Mukamal","year":"2013","journal-title":"Diabetologia"},{"key":"key2024022916234200_ref59-bib59","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","article-title":"Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the Steno Type 1 Risk Engine","volume":"133","author":"Vistisen","year":"2016","journal-title":"Circulation"},{"key":"key2024022916234200_ref60-bib60","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00125-021-05478-4","article-title":"Development and validation of a cardiovascular risk prediction model in type 1 diabetes","volume":"64","author":"McGurnaghan","year":"2021","journal-title":"Diabetologia"},{"key":"key2024022916234200_ref61-bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"Weiner","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key2024022916234200_ref62-bib62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semnephrol.2018.02.002","article-title":"Cardiovascular risk prediction in CKD","volume":"38","author":"Ballew","year":"2018","journal-title":"Semin Nephrol"},{"key":"key2024022916234200_ref63-bib63","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MNH.0000000000000265","article-title":"Cardiovascular risk prediction in people with chronic kidney disease","volume":"25","author":"Matsushita","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key2024022916234200_ref64-bib64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key2024022916234200_ref65-bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-11-1","article-title":"Adaptation and validation of the Charlson Index for Read\/OXMIS coded databases","volume":"11","author":"Khan","year":"2010","journal-title":"BMC Fam Pract"},{"key":"key2024022916234200_ref66-bib66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"key2024022916234200_ref67-bib67","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S2666-7568(21)00088-X","article-title":"Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study","volume":"2","author":"Livingstone","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"key2024022916234200_ref68-bib68","first-page":"67","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Statist Software"},{"key":"key2024022916234200_ref69-bib69","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"key2024022916234200_ref70-bib70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/sim.1621","article-title":"A new measure of prognostic separation in survival data","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"key2024022916234200_ref71-bib71","doi-asserted-by":"crossref","first-page":"b605","DOI":"10.1136\/bmj.b605","article-title":"Prognosis and prognostic research: validating a prognostic model","volume":"338","author":"Altman","year":"2009","journal-title":"BMJ"},{"key":"key2024022916234200_ref72-bib72","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circulation"},{"key":"key2024022916234200_ref73-bib73","doi-asserted-by":"crossref","first-page":"e016003","DOI":"10.1161\/JAHA.119.016003","article-title":"Predicting risk of atherosclerotic cardiovascular disease using pooled cohort equations in older adults with frailty, multimorbidity, and competing risks","volume":"9","author":"Nguyen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"key2024022916234200_ref74-bib74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-157-6-201209180-00002","article-title":"Development and validation of a coronary risk prediction model for older U.S. and European persons in the Cardiovascular Health Study and the Rotterdam Study","volume":"157","author":"Koller","year":"2012","journal-title":"Ann Intern Med"},{"key":"key2024022916234200_ref75-bib75","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/14017431003698531","article-title":"Competing risk analysis of events 10 years after revascularization","volume":"44","author":"Melberg","year":"2010","journal-title":"Scand Cardiovasc J"},{"key":"key2024022916234200_ref76-bib76","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.2337\/dc18-0578","article-title":"Performance of cardiovascular disease risk scores in people diagnosed with type 2 diabetes: external validation using data from the National Scottish Diabetes Register","volume":"41","author":"Read","year":"2018","journal-title":"Diabetes Care"},{"key":"key2024022916234200_ref77-bib77","first-page":"604","article-title":"Are competing-risk models superior to standard Cox models for predicting cardiovascular risk in older adults? Analysis of a whole-of-country primary prevention cohort aged \u2265\u200965 years","volume":"54","author":"Cooper","year":"2021","journal-title":"Int J Epidemiol"},{"key":"key2024022916234200_ref78-bib78","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/2047487315579616","article-title":"Comparison of application of different methods to estimate lifetime cardiovascular risk","volume":"23","author":"Brotons","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"key2024022916234200_ref79-bib79","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies\u2019 consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"JBS3 Board","year":"2014","journal-title":"Heart"},{"key":"key2024022916234200_ref80-bib80","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"key2024022916234200_ref81-bib81","volume-title":"Welcome to the QRISK\u00ae-Lifetime Cardiovascular Risk Calculator","author":"ClinRisk"},{"key":"key2024022916234200_ref82-bib82","volume-title":"What\u2019s Your Heart Age? NHS Health Check","author":"NHS Choices"},{"key":"key2024022916234200_ref83-bib83","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"113","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"key":"key2024022916234200_ref84-bib84","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"key2024022916234200_ref85-bib85","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0140-6736(21)00572-9","article-title":"Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study","volume":"397","author":"Pylypchuk","year":"2021","journal-title":"Lancet"},{"key":"key2024022916234200_ref86-bib86","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"key2024022916234200_ref90-bib90","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref91-bib91","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-207907","article-title":"The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis","volume":"74","author":"Marques","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key2024022916234200_ref92-bib92","doi-asserted-by":"crossref","first-page":"i6755","DOI":"10.1136\/bmj.i6755","article-title":"External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study","volume":"356","author":"Dagan","year":"2017","journal-title":"BMJ"},{"key":"key2024022916234200_ref93-bib93","doi-asserted-by":"crossref","first-page":"i2416","DOI":"10.1136\/bmj.i2416","article-title":"Prediction models for cardiovascular disease risk in the general population: systematic review","volume":"353","author":"Damen","year":"2016","journal-title":"BMJ"},{"key":"key2024022916234200_ref95-bib95","volume-title":"Validation of QFracture Compared with FRAX: Analysis Prepared for NICE 2011","author":"Hippisley-Cox","year":"2011"},{"key":"key2024022916234200_ref96-bib96","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ije\/dyr213","article-title":"Competing risks in epidemiology: possibilities and pitfalls","volume":"41","author":"Andersen","year":"2012","journal-title":"Int J Epidemiol"},{"key":"key2024022916234200_ref97-bib97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-012-2051-5","article-title":"Manitoba Bone Density Program. Competing mortality and fracture risk assessment","volume":"24","author":"Leslie","year":"2013","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref98-bib98","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2589-7500(19)30012-3","article-title":"A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service","volume":"1","author":"Kuan","year":"2019","journal-title":"Lancet Digit Health"},{"key":"key2024022916234200_ref99-bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"key2024022916234200_ref100-bib100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-011-1846-0","article-title":"Pitfalls in the external validation of FRAX","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref101-bib101","doi-asserted-by":"crossref","first-page":"e0244291","DOI":"10.1371\/journal.pone.0244291","article-title":"Fracture incidence in adults in relation to age and gender: a study of 27,169 fractures in the Swedish Fracture Register in a well-defined catchment area","volume":"15","author":"Bergh","year":"2020","journal-title":"PLOS ONE"},{"key":"key2024022916234200_ref102-bib102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.healthpol.2004.12.008","article-title":"Process utility from providing informal care: the benefit of caring","volume":"74","author":"Brouwer","year":"2005","journal-title":"Health Policy"},{"key":"key2024022916234200_ref103-bib103","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","article-title":"Quantifying the utility of taking pills for cardiovascular prevention","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key2024022916234200_ref104-bib104","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1525-1497.1998.00246.x","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"13","author":"Augustovski","year":"1998","journal-title":"J Gen Intern Med"},{"key":"key2024022916234200_ref105-bib105","volume-title":"Can a CT Heart Scan Predict and Prevent Heart Attacks More Effectively Than a Risk Score?","author":"British Heart Foundation"},{"key":"key2024022916234200_ref106-bib106","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1001\/jama.2014.15825","article-title":"Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial","volume":"312","author":"Muhlestein","year":"2014","journal-title":"JAMA"},{"key":"key2024022916234200_ref107-bib107","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-144-5-200603070-00007","article-title":"Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis","volume":"144","author":"Pignone","year":"2006","journal-title":"Ann Intern Med"},{"key":"key2024022916234200_ref108-bib108","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCOUTCOMES.113.000799","article-title":"Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis","volume":"7","author":"Pletcher","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key2024022916234200_ref109-bib109","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1475-6773.2009.01075.x","article-title":"Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes","volume":"45","author":"Timbie","year":"2010","journal-title":"Health Serv Res"},{"key":"key2024022916234200_ref110-bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","article-title":"Measurement of health state utilities for economic appraisal","volume":"5","author":"Torrance","year":"1986","journal-title":"J Health Econ"},{"key":"key2024022916234200_ref111-bib111","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0021-9681(78)90072-3","article-title":"The utility of different health states as perceived by the general public","volume":"31","author":"Sackett","year":"1978","journal-title":"J Chronic Dis"},{"key":"key2024022916234200_ref112-bib112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","article-title":"Best\u2013worst scaling: what it can do for health care research and how to do it","volume":"26","author":"Flynn","year":"2007","journal-title":"J Health Econ"},{"key":"key2024022916234200_ref113-bib113","volume-title":"Best\u2013Worst Scaling: Theory and Methods","author":"Flynn","year":"2014"},{"key":"key2024022916234200_ref114-bib114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40271-019-00391-w","article-title":"A picture is worth a thousand words: the role of survey training materials in stated-preference studies","volume":"13","author":"Vass","year":"2020","journal-title":"Patient"},{"key":"key2024022916234200_ref115-bib115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40271-014-0048-1","article-title":"Risk as an attribute in discrete choice experiments: a systematic review of the literature","volume":"7","author":"Harrison","year":"2014","journal-title":"Patient"},{"key":"key2024022916234200_ref116-bib116","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key2024022916234200_ref120-bib120","first-page":"PA637","article-title":"Preferences for route of administration, frequency and location \u2013 a time-trade-off study in the United Kingdom general population","volume":"20","author":"J\u00f8rgensen","year":"2017","journal-title":"Value Health"},{"key":"key2024022916234200_ref121-bib121","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jval.2016.10.007","article-title":"Health state utilities associated with glucose monitoring devices","volume":"20","author":"Matza","year":"2017","journal-title":"Value Health"},{"key":"key2024022916234200_ref122-bib122","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"key2024022916234200_ref123-bib123","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7326\/0003-4819-150-4-200902170-00005","article-title":"Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering","volume":"150","author":"Pletcher","year":"2009","journal-title":"Ann Intern Med"},{"key":"key2024022916234200_ref124-bib124","doi-asserted-by":"crossref","first-page":"d1672","DOI":"10.1136\/bmj.d1672","article-title":"Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis","volume":"342","author":"Greving","year":"2011","journal-title":"BMJ"},{"key":"key2024022916234200_ref127-bib127","doi-asserted-by":"crossref","first-page":"859","DOI":"10.21105\/joss.00859","article-title":"nomisr: access Nomis UK labour market data","volume":"3","author":"Odell","year":"2018","journal-title":"J Open Source Softw"},{"key":"key2024022916234200_ref128-bib128","doi-asserted-by":"crossref","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"key2024022916234200_ref129-bib129","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/jnnp.51.11.1373","article-title":"A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981\u201386. 1. Methodology, demography and incident cases of first-ever stroke","volume":"51","author":"Bamford","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key2024022916234200_ref130-bib130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/01.STR.20.3.333","article-title":"Incidence of transient ischemic attacks in Oxfordshire, England","volume":"20","author":"Dennis","year":"1989","journal-title":"Stroke"},{"key":"key2024022916234200_ref131-bib131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.326.7379.20","article-title":"Incidence of coronary heart disease in a health authority in London: review of a community register","volume":"326","author":"Sutcliffe","year":"2003","journal-title":"BMJ"},{"key":"key2024022916234200_ref132-bib132","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","article-title":"Variations in population health status: results from a United Kingdom national questionnaire survey","volume":"316","author":"Kind","year":"1998","journal-title":"BMJ"},{"key":"key2024022916234200_ref133-bib133","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/ije\/dyr199","article-title":"Cohort profile: the health survey for England","volume":"41","author":"Mindell","year":"2012","journal-title":"Int J Epidemiol"},{"key":"key2024022916234200_ref134-bib134","volume-title":"NICE DSU Technical Support Document 9: The Identification, Review and Synthesis of Health State Utility Values from the Literature","author":"Papaioannou","year":"2010"},{"key":"key2024022916234200_ref135-bib135","doi-asserted-by":"crossref","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose\u2013response meta-analyses","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"key2024022916234200_ref136-bib136","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"key2024022916234200_ref137-bib137","doi-asserted-by":"crossref","DOI":"10.3310\/hta25160","article-title":"The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs","volume":"25","author":"Herrett","year":"2021","journal-title":"Health Technol Assess"},{"key":"key2024022916234200_ref138-bib138","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"key":"key2024022916234200_ref140-bib140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/2396987317746516","article-title":"The economic burden of stroke care in England, Wales and Northern Ireland: using a national stroke register to estimate and report patient-level health economic outcomes in stroke","volume":"3","author":"Xu","year":"2018","journal-title":"Eur Stroke J"},{"key":"key2024022916234200_ref141-bib141","doi-asserted-by":"crossref","first-page":"e011805","DOI":"10.1136\/bmjopen-2016-011805","article-title":"Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK","volume":"6","author":"Danese","year":"2016","journal-title":"BMJ Open"},{"key":"key2024022916234200_ref142-bib142","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2307\/2530964","article-title":"A Cox regression model for the relative mortality and its application to diabetes mellitus survival data","volume":"41","author":"Andersen","year":"1985","journal-title":"Biometrics"},{"key":"key2024022916234200_ref143-bib143","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/eurheartj\/eht232","article-title":"Longterm impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study","volume":"35","author":"McConnachie","year":"2014","journal-title":"Eur Heart J"},{"key":"key2024022916234200_ref144-bib144","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.117.027067","article-title":"Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke","volume":"136","author":"Heller","year":"2017","journal-title":"Circulation"},{"key":"key2024022916234200_ref145-bib145","first-page":"665","article-title":"\u2018You say treatment, I say hard work\u2019: treatment burden among people with chronic illness and their carers in Australia","volume":"21","author":"Sav","year":"2013","journal-title":"Health Soc Care Community"},{"key":"key2024022916234200_ref147-bib147","doi-asserted-by":"crossref","DOI":"10.3310\/hta20780-c201803","article-title":"Corrigendum: a systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2018","journal-title":"Health Technol Assess"},{"key":"key2024022916234200_ref148-bib148","volume-title":"Non-bisphosphonates for Treating Osteoporosis [ID901]","author":"National Institute for Health and Care Excellence"},{"key":"key2024022916234200_ref149-bib149","doi-asserted-by":"crossref","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess"},{"key":"key2024022916234200_ref150-bib150","doi-asserted-by":"crossref","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol Assess"},{"key":"key2024022916234200_ref151-bib151","volume-title":"Search GP Prescribing Data","author":"OpenPrescribing"},{"key":"key2024022916234200_ref152-bib152","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref153-bib153","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/gme.0b013e318221bacd","article-title":"Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database","volume":"19","author":"Li","year":"2012","journal-title":"Menopause"},{"key":"key2024022916234200_ref154-bib154","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","article-title":"Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink","volume":"31","author":"Morley","year":"2020","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref155-bib155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key2024022916234200_ref156-bib156","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2024022916234200_ref157-bib157","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-012-2240-2","article-title":"The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) \u2013 quality of life during the first 4 months after fracture","volume":"24","author":"Borgstrom","year":"2013","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref158-bib158","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","article-title":"Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS","volume":"29","author":"Svedbom","year":"2018","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref159-bib159","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00198-015-3088-z","article-title":"Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS)","volume":"26","author":"Abimanyi-Ochom","year":"2015","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref160-bib160","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00198-016-3544-4","article-title":"Quality of life, resource use, and costs related to hip fracture in Estonia","volume":"27","author":"J\u00fcrisson","year":"2016","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref161-bib161","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s11136-017-1748-5","article-title":"Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS","volume":"27","author":"Svedbom","year":"2018","journal-title":"Qual Life Res"},{"key":"key2024022916234200_ref163-bib163","volume-title":"Unit Costs of Health and Social Care 2020","author":"Curtis","year":"2020"},{"key":"key2024022916234200_ref164-bib164","volume-title":"Osteoporosis. Quality standard [QS149]","author":"National Institute for Health and Care Excellence"},{"key":"key2024022916234200_ref165-bib165","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","article-title":"FRAX-based assessment and intervention thresholds \u2013 an exploration of thresholds inwomen aged 50 years and older in the UK","volume":"26","author":"McCloskey","year":"2015","journal-title":"Osteoporos Int"},{"key":"key2024022916234200_ref168-bib168","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1805971","article-title":"Coronary CT angiography and 5-year risk of myocardial infarction","volume":"379","author":"The SCOT-HEART Investigators","year":"2018","journal-title":"New Engl J Med"},{"key":"key2024022916234200_ref169-bib169","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.96.1.44","article-title":"Intermittent claudication","volume":"96","author":"Murabito","year":"1997","journal-title":"Circulation"},{"key":"key2024022916234200_ref170-bib170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1053\/euhj.1998.1280","article-title":"Incidence and aetiology of heart failure; a population-based study","volume":"20","author":"Cowie","year":"1999","journal-title":"Eur Heart J"},{"key":"key2024022916234200_ref172-bib172","volume-title":"Accounting for Multimorbidity, Competing Risk and Direct Treatment Disutility in Risk Prediction Tools and Model-Based Cost-effectiveness Analysis for the Primary Prevention of Cardiovascular Disease: A Systematic Review Protocol to Identify Health State Utility Values","author":"Hainsworth"},{"key":"key2024022916234200_ref173-bib173","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/S0266462317000897","article-title":"Performance of ovid MEDLINE search filters to identify health state utility studies","volume":"33","author":"Arber","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"key2024022916234200_ref174-bib174","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1212\/WNL.0b013e3182a9f45f","article-title":"Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study","volume":"81","author":"Luengo-Fernandez","year":"2013","journal-title":"Neurology"},{"key":"key2024022916234200_ref175-bib175","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1089\/jwh.2013.4653","article-title":"Differences between women and men with intermittent claudication: a cross-sectional study","volume":"23","author":"Lozano","year":"2014","journal-title":"J Womens Health"},{"key":"key2024022916234200_ref176-bib176","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ijnurstu.2014.01.009","article-title":"Cost-effectiveness of a nurse facilitated, cognitive behavioural self-management programme compared with usual care using a CBT manual alone for patients with heart failure: secondary analysis of data from the SEMAPHFOR trial","volume":"51","author":"Mej\u00eda","year":"2014","journal-title":"Int J Nurs Stud"},{"key":"key2024022916234200_ref177-bib177","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1161\/CIRCOUTCOMES.115.002592","article-title":"Effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs","volume":"9","author":"Kent","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key2024022916234200_ref178-bib178","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2017.02.149","article-title":"MICE or NICE? An economic evaluation of clinical decision rules in the diagnosis of heart failure in primary care","volume":"241","author":"Monahan","year":"2017","journal-title":"Int J Cardiol"},{"key":"key2024022916234200_ref179-bib179","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/13696998.2018.1454453","article-title":"Prospective utility study of patients with multiple cardiovascular events","volume":"21","author":"Pockett","year":"2018","journal-title":"J Med Econ"},{"key":"key2024022916234200_ref180-bib180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2217\/cer-2017-0029","article-title":"Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication","volume":"7","author":"Vaidya","year":"2018","journal-title":"J Comp Eff Res"},{"key":"key2024022916234200_ref181-bib181","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/heartjnl-2019-315510","article-title":"Quality of life trajectories in survivors of acute myocardial infarction: a national longitudinal study","volume":"106","author":"Munyombwe","year":"2020","journal-title":"Heart"},{"key":"key2024022916234200_ref182-bib182","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/heartjnl-2020-316990","article-title":"Cost-effectiveness of cardiovascular imaging for stable coronary heart disease","volume":"107","author":"Walker","year":"2021","journal-title":"Heart"},{"key":"key2024022916234200_ref183-bib183","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jval.2012.10.013","article-title":"Hospitalization resource use and costs before and after TIA and stroke: results from a population-based cohort study (OXVASC)","volume":"16","author":"Luengo-Fernandez","year":"2013","journal-title":"Value Health"},{"key":"key2024022916234200_ref184-bib184","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ehjqcco\/qcw003","article-title":"Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER)","volume":"2","author":"Walker","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"key2024022916234200_ref188-bib188","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cmpb.2006.01.004","article-title":"Relative survival analysis in R","volume":"81","author":"Pohar","year":"2006","journal-title":"Comput Methods Programs Biomed"}],"container-title":["Health and Social Care Delivery Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2044841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/KLTR7714\/KLTR7714.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2044841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T10:57:17Z","timestamp":1709204237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hsdr\/KLTR7714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":164,"alternative-id":["10.3310\/KLTR7714"],"URL":"https:\/\/doi.org\/10.3310\/kltr7714","relation":{},"ISSN":["2755-0060","2755-0079"],"issn-type":[{"value":"2755-0060","type":"print"},{"value":"2755-0079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"09-2015","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2022","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"06-2022","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}